reports
Autobio Diagnostics Co Ltd: 1 director
A director at Autobio Diagnostics Co Ltd maiden bought 901,200 shares at 55.820CNY and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Svenska Handelsbanken AB (publ): 1 director
A director at Svenska Handelsbanken AB (publ) bought 5,000 shares at 100.850SEK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- ABGSC Financials Research
- Patrik Brattelius
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
- Jerôme Bodin
Believe : T1 2024 toujours en forte croissance mais inférieure à nos a...
>Opinion Neutre réitérée, objectif de cours calé sur l’offre du consortium - Believe a publié hier soir son CA T1 ressorti légèrement inférieur à notre attente avec une croissance organique ajustée de 16% alors que nous tablions sur 20%. Le 1er trimestre a donc été un peu plus mou qu’attendu. Le groupe a tenu sa conférence téléphonique dans la foulée durant laquelle il a indiqué tabler sur une accélération de la croissance organique sur le reste de l’année. Il confir...
- ABGSC IT Research
- Øystein Elton Lodgaard
- ABGSC Financials Research
- Albert Broock
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC IT Research
- Alice Beer
- Nikola Kalanoski
- ABGSC Construct. & Real Estate Research
- Adrian Gilani
- ABGSC IT Research
- Oscar Rönnkvist
- Simon Jönsson
- ABGSC Capital Goods Research
- Karl Bokvist
- Anthony Dick
- Michael Foundoukidis
Michelin : Start to the year broadly in line
>Q1 sales in line, volumes down sharply, price/mix still positive - Yesterday after trading, Michelin reported Q1 2024 sales of € 6,642m, down 5% (-3% at constant exchange rates), broadly in line with expectations (€ 6,679m, ODDO BHF € 6,613m). As expected, volumes were down at the start of the year (-4.1%, consensus -3.4%), even though they already showed a clear sequential improvement (-7.4% in Q4 2023), while the price/mix component remained robust (+0.7% vs consen...
- Nicolas Thorez
Alan Allman Associates : Résultats 2023 mitigés (MOA solide, bottom-li...
>Résultats 2023 : bonne tenue de la MOA mais bottom-line en baisse - AAA a dévoilé hier ses résultats 2023. Pour un CA (déjà publié) de 365.6 M€, en croissance de 14% dont ~1% org d’après nos calculs, le ROA (équivalent EBITDA) ressort à 35.7 M€, légèrement supérieur à notre attente (vs ODDO BHF 34.9 M€). La MOA s’affiche ainsi à 9.8%, quasiment stable y-o-y (-20 pb), une performance honorable dans un contexte de marché moins favorable. Cela tient, selon nous, au posi...
Tim Kirchen appointed Executive Vice President, UPM Raflatac and membe...
Tim Kirchen appointed Executive Vice President, UPM Raflatac and member of the Group Executive Team UPM-Kymmene Corporation Stock Exchange Release (Changes board/management/auditors) 25 April 2024 at 09:45 EEST Tim Kirchen appointed Executive Vice President, UPM Raflatac and member of the Group Executive Team Tim Kirchen has been appointed Executive Vice President, UPM Raflatac. He will be a member of UPM’s Group Executive Team and report to Massimo Reynaudo, President and CEO. Tim Kirchen, born 1980, is currently Senior Vice President, Americas region at UPM Ra...
Tim Kirchen nimitetty UPM Raflatac -liiketoiminta-alueen johtajaksi ja...
Tim Kirchen nimitetty UPM Raflatac -liiketoiminta-alueen johtajaksi ja UPM:n johtajiston jäseneksi UPM-Kymmene Oyj Pörssitiedote (Muutokset hallitus/johto/tilintarkastus) 25.4.2024 klo 9.45 Tim Kirchen nimitetty UPM Raflatac -liiketoiminta-alueen johtajaksi ja UPM:n johtajiston jäseneksi Tim Kirchen on nimitetty UPM Raflatac -liiketoiminta-alueen johtajaksi. Samalla hänestä tulee UPM:n johtajiston jäsen ja hän raportoi toimitusjohtaja Massimo Reynaudolle. Tim Kirchen, s. 1980, toimii tällä hetkellä UPM Raflatacin Americas-alueen liiketoimintajoht...
EQS-News: Constantin Baack takes over as Chief Executive Officer of MP...
EQS-News: MPC Münchmeyer Petersen Capital AG / Key word(s): Personnel Constantin Baack takes over as Chief Executive Officer of MPC Capital AG from Ulf Holländer 25.04.2024 / 08:40 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release Constantin Baack takes over as Chief Executive Officer of MPC Capital AG from Ulf Holländer Ulf Holländer hands over the position as Chief Executive Officer to Constantin Baack after 24 years on the board Ulf Holländer transitions to the Supervisory Board Christian Schwenkenbecher joins the Managem...
EQS-News: Constantin Baack übernimmt Vorstandsvorsitz der MPC Capital ...
EQS-News: MPC Münchmeyer Petersen Capital AG / Schlagwort(e): Personalie Constantin Baack übernimmt Vorstandsvorsitz der MPC Capital AG von Ulf Holländer 25.04.2024 / 08:40 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PressemitteilungConstantin Baack übernimmt Vorstandsvorsitz der MPC Capital AG von Ulf Holländer Ulf Holländer übergibt Vorstandsvorsitz nach 24-jähriger Vorstandstätigkeit an Constantin Baack Wechsel von Ulf Holländer in den Aufsichtsrat Christian Schwenkenbecher rückt als Chief Client Officer in den Vorstand auf ...
- Thomas Vranken
Onward Medical FIRST LOOK: FY23 results as expected, 2024 outlook conf...
Onward reported its FY23 results, and confirmed its FY24 outlook and key milestones. 2024 is set to become the year of its first launch, with ARCEX approval expected 2H24. Meanwhile, the pivotal trial in blood pressure control with ARCIM remains planned to start 2H24. YE23 cash landed at € 29.8m and was complemented with a € 20m equity raise to deliver cash runway into mid-2025. We reiterate our Buy rating and € 9.3 TP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.